All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Capivasertib/Fulvestrant Approval Expands Options in PIK3CA/AKT1/PTEN-Altered HR+/HER2– Breast Cancer

December 22nd 2023

Sara M. Tolaney, MD, MPH, discusses the significance of the FDA approval of capivasertib and fulvestrant in this patient population, highlights the efficacy and notable toxicities seen in the CAPItello-291 trial, and touches on key considerations when selecting between this and other standard regimens following CDK4/6 inhibitor progression.

Sacituzumab Govitecan Plus Pembrolizumab Elicits Antitumor Activity in NSCLC

December 22nd 2023

Sandip P. Patel, MD, discusses the exploration of sacituzumab govitecan in the EVOKE-01 and EVOKE-02 trials in NSCLC and expands on future treatment directions with the agent in this patient population.

Patritumab Deruxtecan BLA Receives Priority Review in NSCLC

December 22nd 2023

The FDA has accepted and granted priority review to the biologics license application seeking the approval of the HER3-directed antibody-drug conjugate patritumab deruxtecan for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non–small cell lung cancer.

A Year of Excellence: 2023 WebMD Elite Choice Award

December 22nd 2023

WebMD awarded Huntsman Cancer Institute at the University of Utah its highest honor, the 2023 WebMD Elite Choice Award.

FDA Approves Label Updates to Include New Data for Axi-Cel in LBCL, Zanubrutinib in CLL

December 22nd 2023

The FDA has approved label updates for zanubrutinib to include data from the ALPINE trial in relapsed/refractory chronic lymphocytic leukemia, and axicabtagene ciloleucel to include findings from the primary overall survival analysis of the ZUMA-7 trial in relapsed/refractory large B-cell lymphoma.

Development of EHR-Integrated Cancer Staging Module Identifies Barriers, Increases Discrete Capture

December 22nd 2023

The implementation and subsequent optimization of a health information technology module within the electronic health record has allowed clinicians across a diverse health care system to identify barriers to improve discrete capture of cancer staging and design solutions to address them.

Alisertib Induces Early Signals of Efficacy in Endocrine-Resistant Breast Cancer

December 22nd 2023

Alisertib as monotherapy and in combination with fulvestrant stands at the forefront of the clinical investigation of selective AURKA pathway inhibition in patients with endocrine-resistant advanced breast cancer, according to Tufia C. Haddad, MD.

Obinutuzumab Use Decreases Incidence of Steroid-Requiring cGVHD After Transplant

December 21st 2023

Utilizing obinutuzumab to enhance B-cell depletion significantly reduced the need for corticosteroids and increased relapse-free survival in patients with steroid-requiring chronic graft-vs-host disease undergoing well-matched hematopoietic stem cell transplant.

NCCN Adds 2 Category 1 Recommendations for Amivantamab in NSCLC Clinical Practice Guidelines

December 21st 2023

The National Comprehensive Cancer Network has updated its Clinical Practice Guidelines for Non–Small Cell Lung Cancer for 2024 to include 2 new category 1 recommendations for amivantamab alongside chemotherapy in patients with treatment-naive, EGFR-mutated advanced NSCLC.

ADCs and Immunotherapy Are Redefining Urothelial Cancer Treatment

December 21st 2023

Bupathi highlights key points that were presented at an OncLive Institutional Perspectives in Cancer, including implications of the EV-302 trial findings; data updates from the phase 1/2 ICRA trial; and future directions for urothelial cancer.

FDA Grants Breakthrough Therapy Designation to BNT323/DB-1303 in Endometrial Cancer

December 21st 2023

The FDA has granted breakthrough therapy designation to the HER2-targeted antibody-drug conjugate BNT323/DB-1303 for use as a potential therapeutic option in patients with advanced endometrial cancer who have progressed on or after treatment with immune checkpoint inhibitors.

Cancer Blood Tests Jumpstart Diagnoses and Targeted Therapy

December 21st 2023

New research led by a UC Davis Comprehensive Cancer Center clinical scientist shows blood tests used to hunt for cancer DNA may help detect cancers faster and guide the use of targeted therapies.

sBLA and NDA Submitted to FDA for Amivantamab and Lazertinib in EGFR-Mutant NSCLC

December 21st 2023

A supplemental biologics license application and new drug application seeking the approval of amivantamab plus lazertinib as frontline therapy for the treatment of patients with locally advanced or metastatic NSCLC with EGFR mutations have been submitted to the FDA.

B7-H4 Offers Potential Treatment Target in a Variety of Solid Tumors

December 21st 2023

The transmembrane protein B7-H4 has emerged as an interesting therapeutic target in multiple solid tumors, with investigators mostly focusing on the development of antibody-drug conjugates aimed at the pathway.

ESR1 Coalteration Treatment Resistance Does Not Impact Lasofoxifene/Abemaciclib Efficacy in ESR1+ Metastatic Breast Cancer

December 21st 2023

The presence of ESR1 coabnormalities, including TP53 and PIK3CA mutations, and CCND1 and FGFR1 amplification, did not demonstrate a negative impact on the efficacy with lasofoxifene and abemaciclib in patients with estrogen receptor–positive, ESR1-mutant metastatic breast cancer.

European Commission Approves New Frontline Indications for Pembrolizumab Plus Chemo in Select GI Cancers

December 21st 2023

The European Commission has approved new indications for pembrolizumab in combination with chemotherapy in select patients with gastric or gastroesophageal adenocarcinoma and select patients with biliary tract cancer.

Quality of Life, Toxicity Weighed Most by Patients When Choosing Metastatic Breast Cancer Treatment

December 20th 2023

Quality of life and adverse effects are key components most patients with estrogen receptor–positive, HER2-negative metastatic breast cancer weigh when choosing an anticancer therapy, according to patient-reported results of an ESR1 QUAlity of Life Survey 3 survey.

Zanubrutinib Improves PFS in Treatment-Naive CLL/SLL, Regardless of Complex Karyotypes

December 20th 2023

Paolo Ghia, MD, PhD, describes the various cohorts of the SEQUOIA study, expands on outcomes from a biomarker subgroup analysis with zanubrutinib vs bendamustine plus rituximab, and more.

New Precision Medicine and Developmental Therapeutics Cancer Clinic Opens at Allegheny General Hospital

December 20th 2023

The Allegheny Health Network Cancer Institute announced today that it has established one of the region’s first clinics dedicated to precision cancer medicine and has appointed nationally recognized medical oncologist Ariel Lopez-Chavez, MD, MS, to serve as director of the new clinic.

Addition of Tucatinib to Breast Cancer Maintenance Therapy Aims to Fill Unmet Need for Patients With Brain Metastases

December 20th 2023

Tucatinib, which inhibits phosphorylation of HER2/3 resulting in inhibition of downstream MAPK and AKT signaling and cell proliferation, has shown promise for patients with brain metastases as the small molecule inhibitor of HER2 can cross the blood-brain barrier.